🚀 VC round data is live in beta, check it out!
Halozyme Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Halozyme Therapeutics and similar public comparables like Cytokinetics, Kelun, Kyowa Kirin, Krystal Biotech and more.
Halozyme Therapeutics Overview
About Halozyme Therapeutics
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Founded
1998
HQ
Employees
423
Website
Sectors
Financials (LTM)
EV
$10B
Halozyme Therapeutics Financials
Halozyme Therapeutics reported last 12-month revenue of $2B and EBITDA of $810M.
In the same LTM period, Halozyme Therapeutics generated $1B in gross profit, $810M in EBITDA, and $512M in net income.
Revenue (LTM)
Halozyme Therapeutics P&L
In the most recent fiscal year, Halozyme Therapeutics reported revenue of $1B and EBITDA of $658M.
Halozyme Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Margin | 84% | XXX | 84% | XXX | XXX | XXX |
| EBITDA | $810M | XXX | $658M | XXX | XXX | XXX |
| EBITDA Margin | 54% | XXX | 47% | XXX | XXX | XXX |
| EBIT Margin | 44% | XXX | 57% | XXX | XXX | XXX |
| Net Profit | $512M | XXX | $317M | XXX | XXX | XXX |
| Net Margin | 34% | XXX | 23% | XXX | XXX | XXX |
| Net Debt | — | — | $2B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Halozyme Therapeutics Stock Performance
Halozyme Therapeutics has current market cap of $8B, and enterprise value of $10B.
Market Cap Evolution
Halozyme Therapeutics' stock price is $69.29.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10B | $8B | 4.0% | XXX | XXX | XXX | $2.67 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHalozyme Therapeutics Valuation Multiples
Halozyme Therapeutics trades at 6.8x EV/Revenue multiple, and 12.6x EV/EBITDA.
EV / Revenue (LTM)
Halozyme Therapeutics Financial Valuation Multiples
As of April 19, 2026, Halozyme Therapeutics has market cap of $8B and EV of $10B.
Equity research analysts estimate Halozyme Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Halozyme Therapeutics has a P/E ratio of 16.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8B | XXX | $8B | XXX | XXX | XXX |
| EV (current) | $10B | XXX | $10B | XXX | XXX | XXX |
| EV/Revenue | 6.8x | XXX | 7.3x | XXX | XXX | XXX |
| EV/EBITDA | 12.6x | XXX | 15.5x | XXX | XXX | XXX |
| EV/EBIT | 15.6x | XXX | 12.7x | XXX | XXX | XXX |
| EV/Gross Profit | 8.1x | XXX | 8.7x | XXX | XXX | XXX |
| P/E | 16.0x | XXX | 25.9x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 28.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Halozyme Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Halozyme Therapeutics Margins & Growth Rates
Halozyme Therapeutics' revenue in the last 12 month grew by 21%.
Halozyme Therapeutics' revenue per employee in the last FY averaged $3.3M, while opex per employee averaged $0.9M for the same period.
Halozyme Therapeutics' rule of 40 is 92% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Halozyme Therapeutics' rule of X is 131% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Halozyme Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 21% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Margin | 54% | XXX | 47% | XXX | XXX | XXX |
| EBITDA Growth | 54% | XXX | 78% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 92% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 131% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $3.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 14% | XXX | 15% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 6% | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 26% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Halozyme Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Halozyme Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cytokinetics | XXX | XXX | XXX | XXX | XXX | XXX |
| Kelun | XXX | XXX | XXX | XXX | XXX | XXX |
| Kyowa Kirin | XXX | XXX | XXX | XXX | XXX | XXX |
| Krystal Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Nuvalent | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Halozyme Therapeutics M&A Activity
Halozyme Therapeutics acquired XXX companies to date.
Last acquisition by Halozyme Therapeutics was on XXXXXXXX, XXXXX. Halozyme Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Halozyme Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialHalozyme Therapeutics Investment Activity
Halozyme Therapeutics invested in XXX companies to date.
Halozyme Therapeutics made its latest investment on XXXXXXXX, XXXXX. Halozyme Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Halozyme Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Halozyme Therapeutics
| When was Halozyme Therapeutics founded? | Halozyme Therapeutics was founded in 1998. |
| Where is Halozyme Therapeutics headquartered? | Halozyme Therapeutics is headquartered in United States. |
| How many employees does Halozyme Therapeutics have? | As of today, Halozyme Therapeutics has over 423 employees. |
| Who is the CEO of Halozyme Therapeutics? | Halozyme Therapeutics' CEO is Helen I. Torley. |
| Is Halozyme Therapeutics publicly listed? | Yes, Halozyme Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Halozyme Therapeutics? | Halozyme Therapeutics trades under HALO ticker. |
| When did Halozyme Therapeutics go public? | Halozyme Therapeutics went public in 2004. |
| Who are competitors of Halozyme Therapeutics? | Halozyme Therapeutics main competitors are Cytokinetics, Kelun, Kyowa Kirin, Krystal Biotech. |
| What is the current market cap of Halozyme Therapeutics? | Halozyme Therapeutics' current market cap is $8B. |
| What is the current revenue of Halozyme Therapeutics? | Halozyme Therapeutics' last 12 months revenue is $2B. |
| What is the current revenue growth of Halozyme Therapeutics? | Halozyme Therapeutics revenue growth (NTM/LTM) is 21%. |
| What is the current EV/Revenue multiple of Halozyme Therapeutics? | Current revenue multiple of Halozyme Therapeutics is 6.8x. |
| Is Halozyme Therapeutics profitable? | Yes, Halozyme Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Halozyme Therapeutics? | Halozyme Therapeutics' last 12 months EBITDA is $810M. |
| What is Halozyme Therapeutics' EBITDA margin? | Halozyme Therapeutics' last 12 months EBITDA margin is 54%. |
| What is the current EV/EBITDA multiple of Halozyme Therapeutics? | Current EBITDA multiple of Halozyme Therapeutics is 12.6x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.